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TIMELINE 
Transplantation tolerance from a 
historical perspective 
was the apparent transplantation equivalent 
of the host-versus-pathogen adaptive 
immune response, but the specific mecha-
nisms governing allograft acceptance 
remained a puzzle. 
The avoidance of rejection 
Bone marrow transplantation, 1953- I 989. 
In experiments inspired by Owen's descri p-
tion of blood-cell chimerism in cobb~f K~oqf D 
CATTLE", and by the recognition by Burnet 
and Fenner) of the observation's signifi-
cance, Billingham, Brent and Medawar l : 
showed between 1953 and 1956 that allo-
geneic spleen and bone marrow (BM) cells 
induce tolerance when they are not rejected 
by the incompletely developed immune sys-
tem of neonatal mouse recipients, and that 
the tolerance extends to donor strain skin 
Thomas E. Starzl and Rolf M. Zinkernagel 
Although transplantat io, immuno logy as a 
distinctive field began w h the development 
of experimental models thaI showed the 
feasibility of bone marrow I ansplantation, 
organ engraftment was accomplished first In 
humans, and was thought for many years to 
occur by drastically different mechanisms. 
Here. we present cur lJiew 0 he concepts of 
allograft acceptance and acquired tolerance 
from a historical perspective, and attempl to 
amalgamate them i to simple and unifying 
rules that might guide improvements in 
clinical therapy. 
Our paradigm of transplantation immunology 
(reviewed in REF. I) had its origin in the nine-
teenth century. After the cellular, humoral and 
complement constituents of the immune 
response were discovered (see TlMW:\E), evi-
dence emerged that an immune reaction was 
responsible for the failure of transplanted tis-
sue and most tumour allografts to survive 
indefinitely". "''hen transplantation research 
declined during and after the First World War, 
these early accomplishments faded . Similarly, 
the significance of the :\EO" .• rK~i TOLER.'''CE 
shown in tumour and viral-infection models 
was not fully appreciated until Burnet's for-
mulation of the tolerance and OO:vJ.- SELECTIO. 
hypothesis'. Finally, the phenomenon of 
1~1 ~ 1l:"b IC:\Of(A :\CE was first shown in 1934 
(REF.4 ), but discounted until its rediscovery 
many years later-;.6. 
The immunological basis of rejection 
Modern transplantation immunology is often 
dated to the experiments by Medawar in 1944, 
which showed that skin allograft rejection is a 
HOST-\'ERSl'S -GR..FT (HVG) response', the cell-
med iated features of which were later defined 
by Mitchison8 The term maior histocompati-
bility complex (MHC) was introduced by 
Gorer, Lyman and Snel19 for the genetic locus 
that encodes antigens associated ",>ith allograft 
rejection, tumour surveillance and other 
expressions of cell-mediated immunity. The 
MHC-restricted mechanisms ofT-cell recog-
nition of, and response to, antigens, viruses and 
other intracellular microorgan.isms were eluci-
dated in the 1970s (reviewed in REF. 10). 
i':AT!1 RE REV IEWS 1 fMMr~lildv 
:\O:-:-CYTOP.'T}nc MfCollodKD-y; f p~lp ( for exam-
ple, lymphocytic choriomeningitis virus 
(LCMV) in mice) are controlled primarily 
by cytotoxic T lymphocytes (CTLs) that rec-
ognize as 'non-self' host cells which display 
complexes composed of self-MHC mole-
cules and pept ides derived from the infect-
ing microo rgan ism. Allograft rejection 
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Fig re 1 I Old and new views of transplantation immunology. a I Illustrates the eany 
conceptualization of immune mechanisms in organ transp:antation in ,terms of a unidirec ional host· 
versus-graft (H G) response. Although this readily exr;!ained organ rejectbn. rt limrted possib!e 
explanations of organ engraftment. b I A mirror image of (a) and depicts the early undefstanding of 
successful bone marrow (8 M) transplantation as a C0mplete replacement o f the recipient immune system 
by that of the donor. with the potential comprlCatio of an unopposed Ie hal unidirectional graft -versus -
host (GVH] response: that is. rejection of the recipient by the graft. e I Shows the current vie-N of 
bidirectional and reciprocally modulating immune responses of coexisting i une-competent cell 
POPUlatIonS that lead to organ engraftment, despite a usually dominant HVG reactl()(1. The transplanted 
organ. which onitiaily loses most of its passenger leukocytes. apparently remains an imponant site fOf 
donor precursor and stern celis {bone s~houetteF<T K d I Represents the current conceived mirror image of 
(e) and shows the reversal of the size proportions of the reciprocally modulating donor and recip.en: 
populations of immune cells a er successful 8 M ranspiantalion. 
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". failure 
TIme after organ transplantallon 
Fl9ure 21 Contemporaneous HVG (upright curves) and GVH (inverted curves) responses following 
organ transplantation. If some degree of reciprocal clonal exhaustion IS not induced and maintained (usually 
requiting protectrve Immune suppression), one cell population will destroy the other. In contrast to the usually 
dominant host versusllraft (HVG) reac!Kxi of organ transplantatJOn (shown here), the graft·versus·host (GVH) 
reactron usually IS dominant 11"\ the OJ1oab1ated bone marrow recipient , Therapeutic failure with erther. type of 
transplantation im~res the irebtlity to contrd are, the other. or both of the responses. 
allografts. This model is a nalogous to suc· 
cessful BM-cell tran sp lantatio n in humans 
whose immune-d e ficiency diseases make 
host cytoablation unnecessary U During 
1955-1956, similar tolerance was induced in 
adult mice whose m ature immune system 
was cytuablated with supralethal total body 
irradiation (TB[)", T he mouse model 
evolved into clinical BM transplantation for 
d wide range of indica tionsn 
The avoidance of lethal GIVlFT-VER.SUS-HOSf 
UISWE (GVHD) in the exllerimental tolerance 
models and in humans requires a close tissue 
match. Until human-leukocyte-antigen (HLA) 
matching became aVJilable in 1%8, a decade 
after the discovery by Dausset and van Rood of 
the first HLA antigens, llrolonged surviyD~ after 
clinical BM transplantation was Limited to a 
single case l 6• GV HD seemed to be a m irror-
image version of tissue and organ rejection 
(HVG) in that the host (FI G. IbJ, rather than the 
graft (FIG. la), was the immune target 
The unidireuional ~fluba - lnfmelCvq b ­
REAcn o a~sdysI introduced in 1964, became 
widely accepted 'minitranSlllant models', rei.n-
forcing the idea that one-way immune reac-
tions - VH or HVG - were induced after 
BM and organ translliantation , respectively, 
Accordingly, successful BM transpbntation 
was generally viewed as total replacement of 
the recipient immune apparatus, even after 
the discovery in 1989 that rec1llient leukocytes 
could be found in the blood of essentially all 
human "comlliete donor BM chimeras"' ? 
The early hypothesis that donor and recipient 
immune-co mpete nt ceUs might coexist, 
become mutually non-reactive and even 
fun ct ion collabo rat ively (for example, in a 
Timeline I! Major developments in transplantation 
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Gore< <YXI Sre4I C1scover mcv<."e 
map tostxetrpalibokt', complex 
IIof-CI (An earleo i~ge 
so pliO'! had tear. pulJ/lStla;I 
byGae< n 19371 
:JescnpllOO by Franc!' 
surgecns of rena 
lrMsPantalJOO II) 1I1e peI-.ic 
OC8tOl'1 as pertCln1fld 
esseotJally urTTlOOt[ed t y 
joint response to a new infection)" '· lacked 
experimental SlIPp<:lrt and was abandoned. 
Clinical organ transplantation, 1959-1991, 
The strategy of co-transplanting BM and skin 
allografts to sllpralethally irradiated mice was 
extended in the late 19505 by John Mannick 
and David Humdo kidney/ BM translllanta-
tion in irradiated beagle and outbred dogs, 
but yielded only a single su rvival exceeding 
I month (73 day ). Although the survival of 
dog kidney transplants \-vas ven worse when 
the ddjund 8M was omitted. ix huma n con-
ditioned with sublethal doses of TBI (4.5 y) 
achieved renal allograft function for at least 
I year ( the first in Boston and the next five 
in Paris)20-22 , The era of drug immuno ullP-
ression then bega n after Schwartz and 
Dameshek!.l showed that the anti -leukaemic 
drug 6- mercaptopurinc was immunosuppres-
sive in rabbiL. When about 5% of dog kidney 
recipien ts treated by Caloe and Zukoski with 
6-mercaptopurine, or its analogue azathio-
prine, survived for LIOO days, human trials 
were u.ndertaken by Murray nd colleague,"', 
I n the sixth case of kidney transplantation, a 
renal allograft from a non-related donor func-
tioned for 17 months after its translliantation 
under azathioprine-based therap/;, 
At first, the results \, 'th drug therapy were 
no better than with TBI. However, when la rge 
doses of predniso ne were added to azathio · 
prine in resllon e to c1in i 'ally diagno, ed 
rejections, two key observations were made, 
as described in the titl" 0f a rLtJort of ten cast's: 
"The reversal of rejection in human renal 
homografts with subsequent development of 
homograft tolerance"!" . The partial toleran 
referred to the time-related diminution of 
dependence on immun05u ppression, which 
eventually was stollped"" in two of the llatients 
whose grafts still function after 39 Y MS . 
, 1 'T'oO" 
pCth~ , ""j Damesncl< 
oso""'" Cl'UJ 
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Table 1 1 Differences of organ and bone marrow transplantation 
Feature Organ Bone marrow 
Host cytoablalion No Yes' 
HLA matching Not essential Critical 
PrinclpaJ complicatiorl Rejection GVHD 
Immunosuppression free UiYvOmmon Common 
Term :or success Acceptance Tolerance 
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reciprocal clonal exhaustion, followed by 
peripheral clonal deletion"( FIG. 2 )l l . Although 
this hypothesis has been validated experi-
mentallylK~··gp I the molecular pathways of 
deletion-associated apoptosis observed in 
transplant models are not yet full y under-
stood. Moreover. the role of the late 
microchimerism has been controversialJ9 . 
'This therapeutic ste;J allows a relatively unopposed graft-versus·host reaction and accounts (Of the other 
differences GVHD. graft ·versus-hos! diease: HLA. human leukocyte antigef1. ~=ffimmune ignorance») 
cyve believe that antigen that fails to reach orga-
nized lymphoid collections is ignored by the 
immune system,a. In an early example, Stone, 
Owings and Gey' reported that parathyroid 
tissue, which had been cultured for 2 weeks 
and transplanted into loose areolar subcuta-
neous tissue, functioned for prolonged peri-
ods in dog and human recipients. Long 
regarded as not credible, their findings are 
explained, in retrospect, by two features of the 
procedure. The first was the choice of a subcu-
taneous implantation site. which, like other 
privileged sites (for example, hamster cheek 
pouch and brain), has limited lymphatic 
drainage. Illustrating this principle in 1957, 
In 1966, heterologous anti-lymphoid globulin 
(AlG) was added in a triple-agent protocoP7 
that was used for the first successful trans-
plantation of the human liver in July 1967 
and heart in January 1968. 
The repeated demonstration that organ 
transplantation was feasible without adjunct 
B~ cells, together wi th the striking differ-
ences between organ and BM transplantation 
(TABLE I l,led to a consensus by the early 1960s 
that organ engraftrnent did not involve donor 
leukocyte chimerism. This conclusion osten-
siblywas congruent .... ith the identification of 
the 'sessile' and/or recirculating passenger 
is, microchi.merism) were shown in 1992 in the 
tissues or blood of 30 long-surviving human 
liver or kidney allograft recipientsl l.J2. Organ 
engraftrnen t (AG. i c j and BM -cell engraftment 
(FIG. td) seemed to be mirror images with 
reversed proportions of donor-recipient 
haematolymphopoietic cells, placing both in a 
continuum ofleukocyte chimerism-associated 
tolerance models that could be related to the 
neonatal mouse experiments of Billingham, 
Brent and Medawar'2, and to Owen's original 
observation of blood-cell chimerism in 
freemartin cartle' 1 • 
leukocytes of BM origin contained in all Mechanisms of non-reactivity 
organs, asIt~e immunogenic component of @ Chimerismand clonal deletionKc~~DgK E.XHAUS-
allografts-' -·'". ""hen 1l was subsequently TIOl' was postulated between 19;:,9 and 1968 
learned that most of these 'passenger leuko· to explain acquired non-reactivity to a variety 
cytes' are replaced in the eng rafted organ by of antigens2JJJ..l<, including allogeneic cells IS 
comparable recipient cells, it was assumed and, in 1969, as the basis of organ toleranceJ;. 
that the donor leukocytes had undergone However, the existence and importance of 
immune destruction either \o;ithin the graft or this mechanism have only been formally 
after their migration to host lymphoid established since 1990 (REFS 36.m. With the 
organs, with selective preservation of the finding in 1992 of microchimerism years after 
specialized parenchymal cells of the organ. transplantation in surviving organ recipients, 
The resulting explanation of organ engraft- it was deduced that the crucial period for allo-
ment by means other than the chimerism- engraftment was immediately post-trans-
associated mechanisms ofBM transplantation plantation and consisted of " ... [acute] 
was not challenged until small numbers of responses of coexisting donor and recipient 
multilineage donor haematopoieticcells (that [immune 1 cells, each to the other, causing 
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Frey and Wenk showed that no immune 
response is induced by otherwise sensitizing 
chemicals if the antigen is prevented from 
migrating to draining lymph nodes or spleen, 
an observation su bsequently extended to skin 
allografts by Barker and Billingham;. 
The second feature of the Stone proce-
d ure became apparent with the demonstra-
tion by Lafferty and co-workers6 that tissue 
culture comparable with that used 4 decades 
earlier in the parathyroid experiments 
depletes endocrine tissue of passenger leuko-
cytes that are capable of migrating to host 
lymphoid organs. Similarly, allografts lose 
immunogenicity when their passenger leuko-
cytes are removed from tissues or organs in 
'parking experiments':lS-lC or by other means. 
DII~ar S"""'S ~~a1 
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Box 1 I Analogies between immune responses to infections or transplants 
d 
Immune ignorance 
of or L lJ(esence 
M- or L-depeI1dent partial 
deletional toleranCe 
and/or memory 
1-- M or L antigen 
b 
e 
Stenlimg immune 
elimination of M or L 
.. . ~ ..... 
More complete M or L 
efrmination than in d 
Immune respoose 1 
c 
Delelional tolerance 
to M or L 
Persistence of strong immune 
responses; large quantity 
01 M or L a'1tigen 
The analogies between the adaptive immune response or non-response (dashed lines) induced 
by the antigen of non-cytopathic microorganisms (M) and the analogous migratory leukocytes 
(l ) of allografts (solid lines) have been obscured by the presence of contemporaneous host-
versus-graft (HVG ) and graft-versus-host (GVH) responses after transplantation and the 
additional factor of therapeutic immunosuppression. Under circumstances of both infection 
and transplantation, the immune response or non-response is regulated mainly by the 
migration and localization of the antigen. a I If the antigen fails to reach organized host 
lymphoid tissue, as occurs with the extralymphatic spread of an infection (for example, the 
human papilloma (wart) virus), there is no immune response (immune ignorance). Similarly, 
avoidance of host lymphoid organs by transplanting tissue to privileged sites or by depleting 
the allograft of passenger leukocytes might allow prolonged survival of'Stone-Lafferty' 
transplants, without evolution of donor-specific non-reactivity providing the mobile antigen 
(l) remains extralymphatic. Rejection of the graft can often be precipitated by leakage of graft 
cells in to the blood or lymph circulation (for example, after an infection or trauma" or an 
immuniz.ing injection of donor cells6.2'1. b I Illustrates the immWle elimination of a spreading 
non-cytopathic microorganism that has reached host lymphoid organs and induced an antjgen-
specific response. The outcome is comparable with the rejection of an outlying organ after its 
passenger leukocytes migrate to host lymphoid organs and jnduce an anti-donor response. 
After complete removal of the antigen, the immune response subsides. c I Depicts how the 
persistence of mobile live antigen that has access to host lymphoid organs can exhaust and 
delete the antigen-specific immune response. With infection, this might result in a stable carrier 
sta te (for example, the viral hepatitides, or lymphocytic choriomeningitis virus infestation). 
The transplant analogy is 'complete' repopulation of a recipient by donor bone marrow (BM)-
derived cells after pure stem-cell transplantation to a severe combined immune deficiency 
(SCID) mouse, or after the less complete replacement (macrochimerism) with clinical BM 
transplantation to a host whose immWle response is weakened in advance by cytoablation or 
cytoreduction. This kind of tolerance in organ recipients is most often associated with 
macrochimerism'·'. d I Represents the acute control of an infection by incomplete elimination of 
microorganisms, resulting in cellular plus an tibody 'memory' sustained by the residual live 
antigen (for example, herpesvirus). In the transplantat ion analogy, partial deIetional tolerance 
induced at the outset under immunosuppression might be sustained by the residual donor cells 
(microchimerism) with, or sometimes without, the aid of immWlosuppression. e I Shows more 
complete elimination of mkroorganisms than in Cd) with 'memory' (for example, tuberculosis 
or measles). In the transplantation analogy, survival of the minority population ofleukocytes 
requires continuous immunosuppression . f I Illustrates the survival of a large quantjty of 
microorganisms despite a strong persistent immune response, resulting in acute-chronic 
infection and a spectrum of immunopathology (for example, chronic aggressive hepatitis). 
The transplantation analogy is chronic rejection or GVHD, which might be refractory to 
treatment with immunosuppression. 
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The reduced immunogenicity has bee n 
explained by the elimination of leukocyte 
subsets expressing MHC class II antigens 
or co-stimulatory molecules, such as B7 
(CD80/86) - fo r examp le, donor dendritic 
cells· '. However, passe nger leukocytes might 
be immunogen ic primilrily because they can 
migrate to lymphoid organs, whereas the fixed 
parench yma l e lls ge nerall y cannot. The 
results of experiments wit.h fra ctionated liver 
cell suspensio ns·z a nd with tumour cells lack-
ing MH class 11 or so-called 'second signals'·' 
are consistent with this alternative hypothesi . 
Immune ignoraJl e ufheart allografL'i bas 
been d efinitivel y s tudied dur in g the past 
5 yea rs in mu ta n t (aly/ll ly) mit.: th at have 
normal T lymphocytes .mct a spleen, but lack 
Peyer's patches and lymph nodes. Ca rd i<lc 
allogra fts drained into the circulation by vas-
cular anasto mosis are indolently rejected, but 
when sp len ectomy is a lso performed, the 
hearts are permanently accepted". In addi-
tion to exemplifying immune ignora nce, the 
results con tradi cted the hi sto ri cal dogmas 
that the imm une response to primarily vas -
culari ze d organs does no t require the pres-
ence of hos t lymp ho id orga ns, and that 
intragraft res ponses are g nerated 'direc tly' 
in the transplanted o rg<ln. 
Collaborative mechanisms 
With th . recognit io n in the 19905 that the key 
event in allograft a ceptance is cell migration 
and relocation ' l and that th e adaptive 
imm une re ponse to lion- cytopathic organ -
isms is determined by the m igration pa tterns 
of the path ugc n<o .• " th e analogies be t> ... een 
infectiun and transplantat ion shown in BOX 1 
were obvious. In essence, the do se, ki netics 
and loca li zation of an ti ge n in or out side 
lymphatic tissues regulate immune rcs pon-
siven es:; or un responsiveness not only 
agai ns t in fectio n and allogra fts, but also 
against tumou rs ,nd self. An ada ptive 
immune res ponse could then be viewed a, 
"a balance between pote ntially reactive lym-
phocytes versus th e com pos ition, qu antit y, 
kinetics, and distribution o f antigen (foreign 
or extralym phatic self) within the host"I . 
In th is co ntext, the pr . umably raTe Sto ne-
Lafferty graft rBOX 1 •• 1 is ignored beca use it 
contains so few leukocytes capable o f migrat-
ing to organi l.ed hos t lymph oid collections . 
By contrast, the t.ransplan t outcomes (includ-
ing irreversible a ute rej ct io n; ROX Ib) are 
analogou . with those foil wing spr adin g 
blood-bo rn e in fec tions by non-cytopat hic 
microorganisms, in which variable combina-
tion s of clonal exhaust io n-de letion and 
immune igno rance m ight result in degrees of 
respon sive ness an d non- re ponsiveness. 
www.nature.com / reviews /lmmu nol 
Glossary 
CLO\AL HHAL SnO" 
:\ slat e of non-rt:activilY whe n all prc\,."1.1rSOr 
lymphocyte< a re induced by persistent an t igen (s) to 
tx .... o me effector ceils. pu rg-ing the im mune -response 
repertoire of this specifiClt i (s). 
CLO\.-IL SELECTIO\ 
In Bumt!', origin I h'l>Oth<>is (1 949). ant ibodv 
synthe'iis nccurr~d afte r an ant igen locked onto a 
membrane· b<) und receptor .( a vers io n o f the antibody) 
at the :surbce of an immllnocy tc. In th e m id· to-late 
1 950s, th is even t was postu lated to be .: Ional by Ierne, 
Talmage and Bumet. 
FREE\ il RTI \ C,Tfll 
'Fraternal t\,'ins' whose two placen tas fus.e aJJowing 
fe tal cross circulation, with ind uctio n of mutual specific 
nonreactiy~lv· 
GRA FT·VERSL:S-HOST DISEASE 
(GV HD). The immu ne reac tion again st a g raft 
rec ipiem mounted by immune-com pe-lent cells of 
a graft . 
At one extreme, clonal exhaustion induced 
by overwhelming numbers of leukocytes 
(BOX Ie) might allow unrestricted subsequent 
passage of donor cells between lymphoid 
and non-lymphoid compartments. 
With less-complete deletion, cells that sur-
vive primary exposure to Iym phoid organs 
leave the blood and lymphoid tissues after 
30--60 days and move to host non-parenchy-
mal tissues and organs (for example, skin and 
heartP~-fSF or back to the transplanted organ·7• 
If sufficient numbers of these cells steadily 
em igrate from the extralymphatic sites to 
host lymphoid organs, the clonal exhaustion 
induced at the outset might be perpetuated 
with or without maintenance immunosup-
pression (BOX Id,e). If this traffic is minimal 
or irregular, however, the donor-specific 
responses might lead instead to acute (or 
chronic) organ rejection or permanent recipi-
ent sensitization; experimental variables that 
might tip the balance towards tolerance or 
rejection have been shown by Anderson and 
MatzingerS in mouse experiments. Even with 
the sustained presence of chimerism, the per-
sistence of CTL and antibody responses might 
result in chronic rejection or GVHD (BOX 10_ 
What regulates alloimmune responses? 
We have not discussed here the large body of 
historical' and recent work indicating the 
potential importance of immunoregulatory 
T cells and other changes in the host immune 
response for the mediation of immunity or 
tolerance. Particularly intense interest has 
focused on antigen-non-specific,9 and anti-
gen-specific T cells50 that can downregulate 
both autoimmune and alloimrnune responses. 
I\ i\T ll RE REVI E\ I' S I IMMUNOLOGY 
HOST VERSl:S GRAFT 
( HVGl . Tho im mune reaction mounted bv the host 
aga inst grafted tissue or an o rp n from the same species 
(alloresponse) o r a d iffere nt species (xenoresponse). 
1.\1\11,;:>:£ IG\OR.\ \ a 
Failu re of the immune resp<.Jnse to recognize the presence 
of antigen that docs not reach o rganized lymphoid tissue. 
>;blyK~ei TOLERA\ CE 
The development of specific immune non-reacrrviry to 
an tigen introduced during fe tal or early postnatal life, 
before marurarion of the immune system_ 
\O\-O TOPATH IC ,\I ICRoo RG .. ,SIS\! 
A D~rusF bacteria, p ro lOzoa, fu ngus or micropa.rasite that 
d<xs not kill host cel ls and can be accommodated in 
ways that allow the coexistence of hO;St and pathogen . 
~[[ u£a LH1PHOCYTE ofK~cnly 
(MLR)' A t issuc-culture techni ue introduced by 
Barbara Sain and by Fritz Bach and Kurt Hirschom in 
1964 for in vitro tes ting of T ·celi reactivity_ 
In addition, immature donor dendritic celJs 
might prolong organ allograft survivaPI in 
contrast to mature dendritic cells that effi-
cientlyelicit rejection'!, 
Immunoregulation by such subsets of spe-
cial recipient or donor immune cells, alone or 
in concertS], could be important in future 
strategies of clinical transplantation. The 
same might be true of controlled changes in 
the host cylokine profile, or of the deliberate 
production of idiotypic or 'enhancing' anti-
bodies. Elucidation of these frequently 
reported, but still poorly understood, regula-
tion mechanisms will be necessary for their 
efficient exploitation. For now, we argue that 
the clinical and experimental observations in 
transplantation are most comprehensible 
in terms of antigen dose, localization and 
time during which the antigen is in organized 
lymphoid organs. 
Clinical implications 
From the historical perspective reviewed here, 
it is possible to analyse what has been, and 
what might be, accomplished in clinical 
transplantation. Except for Stone-Lafferty 
grafts, the persistence of donor haematopoi-
etic cells (that is, chimerism) above some 
threshold required to maintain the clonal 
exhaustion induced at the outset is a neces-
sary condition for long aLlograft survival. 
Reciprocal deletion of the characteristic dou-
ble immune response of transplantation 
evolves spontaneously in some experimental 
organ transplant models (especially with 
leukocyte-rich liver allografts) 16, but 
immunosuppression is usually required to 
prevent one immune cell population from 
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destroying the other (that is, rejection or 
GVHD) long enough for the deletion to 
occur (FIG. 2). 
However, the chimerism-dependent clonal 
exhaustion, might be subverted by inappro-
priate post-transplant immunosuppression. 
Although over-immunosuppression can shut 
down clonal activation and prevent organ 
allograft rejection, which allows many of the 
donor leukocytes to survive and migrate to 
non-lymphoid sites, the further movement 
and pleiotropic immunological effects of 
these cells is unpredictable. Consequently, 
neither the presence nor quantity of 
microchimerism can be used to accurately 
guide managemen~r1KKlDlK 
By contrast, the donor-specific clonal 
expansion of the conventional BM recipient 
is reduced enough by prior cytoablation to 
be efficiently deleted by the donor leuko-
cytes before these in fused cells are rejected, 
with minimal dependence on immunosup-
pression_ The widespread use of combined 
BM-organ transplantation in cytoablated 
recipients has been barred so far by the many 
parameters involved, of which the most 
restrictive is the need for a histocompatible 
donor for avoidance of GVHD. 
«Except for Stone- Lafferty 
grafts, the persistence of 
donor haematopoiet ic c lls 
(that is, chimerism). __ is a 
n ecessary condition for 
long allograft survival." 
Compromise strategies between the radi-
cally different regimens of BM and organ 
transplantation have been extensively tested. 
The prototype compromise consists of 
donor BM-cell infusion after weakening the 
recipient's immune responsiveness in 
advance by non-myelotoxic cytoreduction 
(for example, with sublethal irradiation or 
anti-lymphoid antibody preparations), and 
then the use of low doses of immunosup-
pression after transplantation. Production of 
'mixed macrochimerism' with acceptably few 
GVHD complications has been reported in 
rodents and inbred miniature pig organ-
transplant models, and in a small series of 
patients with haematological disorders given 
BM cells from one HLA haplotype-matched 
familial donors'J_ In simpler non-conditioning 
protocols first used clinically in 1976 by 
Monaco and co-workers", donor BM cells 
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have been administered to human organ 
recipients treated with heavy (that is, poten-
tially anti-tolerogenic) conventional immuno-
suppression. Despite a manifold increase in 
microchimerism in several trials, drug free-
dom has not been achieved except, apparently, 
in recent recipients of familial kidneys who 
were given megadoses of donor BM cells in 
Alunedabad, India5; . 
The value of donor pretreatment com-
bined with minimal post-tranSplant immuno-
suppression has been suggested by the perma-
nent donor-specific tolerance achieved 
without adjunct BM cells in 12 monkey kid-
ney recipients that were conditioned with a 
depleting dose of immunotoxin and then 
treated with a 14-day course of deoxyspergua-
line afterward56 • Although such short-term 
protocols regularly allow the induction of tol-
erance in rodents, they have not been used 
clinically. In the historical clinical experience, 
tolerance after human kidney transplantation 
has been rarely observed, and almost exclu-
sively when the 'weak' immunosuppressant 
azathioprine was administered before and 
after transplantation, adding pred.nisone 
only for overt rejection 26 . Drug indepen-
dence has been observed far more frequently 
after transplantation of the liver, but in large 
numbers only when the original immuno-
suppression was with azathioprine-based 
regimens that included pretreatment with 
ALG, or in patients who were weaned from 
tacrolimusi:·.;s . 
It might be possible to achieve drug-free 
tolerance with organs less well-endowed with 
leukocytes than the liver, using a clinical pro-
tocol of host conditioning with ALG and 
minimal post-transplant immunosuppres-
sion that was introduced in 1966 (REF. 27), but 
ultimately abandoned. Armed with modem 
drugs, including powerful anti-lymphoid 
antibody agents, a markedly reduced need for 
early and maintenance immunosuppression 
( including nearly complete elimination of 
prednisone) has been reported from several 
centres. In Cambridge (United Kingdom), 
CaIne et al. 59 have treated cadaver kidney 
recipients with a few perioperative doses of a 
humanized depleting anti-CD 52 monoclonal 
antibody (T and B cell plus monocyte reac-
tive), followed by low-maintenance doses of 
cyclosporine alone. 
Conclusion 
Although much of the progress in transplan-
tation has depended on the development of 
increasingly potent immunosuppressants, 
elucidation of the mechanisms of allograft 
acceptance has set the stage for more d.iscrim-
inating use of these agents. Theoretically, it 
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«Theoretically, it should be 
possible in the futur to 
apply immunosuppression 
and/or immunostimulation 
in just the right balanced 
way to either achieve 
immunolgical indifference 
(ignorance) . .. or to obtain 
stable drug-free and 
antigen-dependent T-cell 
exhaustion and chimerism.') 
should be possible in the future to apply 
immunosuppression and/or immunostimu-
!ation in just the right balanced way to either 
achieve immunological indifference (igno-
rance) in some cases, particularly with hor-
mone-producing cells and small organs, or to 
reliably achieve the perfect equilibrium of 
mutual immune reactivity and T-cell exhaus-
tion or to obtain stable drug-free and antigen-
dependent T-cell exhaustion and chimerism. 
A universally applicable protocol for organ 
transplantation will probably be some mod-
ernized version of the empirically derived 
flexible formulas that originally made organ 
transplantation a practical patient service. 
The key therapeutic principles are: first, recip-
ient pretreatment using antibodies or other 
modalities for conditioning; and second, 
minimal short-term immunosuppression 
after transplantation. The value of adjunct 
donor haematolymphopoietic cells should 
then become apparent. 
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